Skip to main content
Top
Published in: Journal of Hematology & Oncology 1/2023

Open Access 01-12-2023 | Neutropenia | Correspondence

Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium

Authors: Jiazheng Yu, Siyu Wu, Rong Li, Yuanhong Jiang, Jianyi Zheng, Zeyu Li, Mingyang Li, Kerong Xin, Xiaojiao Guan, Shijie Li, Xiaonan Chen

Published in: Journal of Hematology & Oncology | Issue 1/2023

Login to get access

Abstract

Antibody–drug conjugates (ADCs) combine the cytotoxicity of small-molecule drugs with antibody targeting. Due to their precise and powerful effect, they have become a new hotspot and an important trend in the research and development of anti-tumor antibody drugs. Every year, exciting new developments and innovations in the treatment of urological tumors are introduced at the American Society of Clinical Oncology-Genitourinary (ASCO-GU) Cancers Symposium. In this article, we summarize some of the most impressive advances in new clinical trials and clinical data on ADCs in the 2023 ASCO-GU Cancers Symposium for the treatment of urothelial carcinoma.
Literature
1.
go back to reference O’Donnell PH, Rosenberg JE, Hoimes CJ, Petrylak DP, Milowsky MI, McKay RR, et al. Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): subgroup analyses of confirmed objective response rate (cORR) from EV-103 cohort K. J Clin Oncol. 2023;41(6_suppl):499.CrossRef O’Donnell PH, Rosenberg JE, Hoimes CJ, Petrylak DP, Milowsky MI, McKay RR, et al. Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): subgroup analyses of confirmed objective response rate (cORR) from EV-103 cohort K. J Clin Oncol. 2023;41(6_suppl):499.CrossRef
2.
go back to reference Kamat AM, Steinberg GD, Inman BA, Kates MR, Uchio EM, Porten SP, et al. Study EV-104: phase 1 study of intravesical enfortumab vedotin for treatment of patients with non-muscle invasive bladder cancer (NMIBC)—trial in progress. J Clin Oncol. 2023;41(6_sippl):TPS582.CrossRef Kamat AM, Steinberg GD, Inman BA, Kates MR, Uchio EM, Porten SP, et al. Study EV-104: phase 1 study of intravesical enfortumab vedotin for treatment of patients with non-muscle invasive bladder cancer (NMIBC)—trial in progress. J Clin Oncol. 2023;41(6_sippl):TPS582.CrossRef
3.
go back to reference Tagawa ST, Balar AV, Petrylak DP, Rezazadeh A, Loriot Y, Flechon A, et al. Updated outcomes in TROPHY-U-01 cohort 1, a phase 2 study of sacituzumab govitecan (SG) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI). J Clin Oncol. 2023;41(6_suppl):526.CrossRef Tagawa ST, Balar AV, Petrylak DP, Rezazadeh A, Loriot Y, Flechon A, et al. Updated outcomes in TROPHY-U-01 cohort 1, a phase 2 study of sacituzumab govitecan (SG) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI). J Clin Oncol. 2023;41(6_suppl):526.CrossRef
4.
go back to reference Petrylak DP, Tagawa ST, Jain RK, Bupathi M, Balar AV, Rezazadeh A, et al. Primary analysis of TROPHY-U-01 cohort 2, a phase 2 study of sacituzumab govitecan (SG) in platinum (PT)-ineligible patients (pts) with metastatic urothelial cancer (mUC) that progressed after prior checkpoint inhibitor (CPI) therapy. J Clin Oncol. 2023;41(6_suppl):520.CrossRef Petrylak DP, Tagawa ST, Jain RK, Bupathi M, Balar AV, Rezazadeh A, et al. Primary analysis of TROPHY-U-01 cohort 2, a phase 2 study of sacituzumab govitecan (SG) in platinum (PT)-ineligible patients (pts) with metastatic urothelial cancer (mUC) that progressed after prior checkpoint inhibitor (CPI) therapy. J Clin Oncol. 2023;41(6_suppl):520.CrossRef
5.
go back to reference Grivas P, Pouessel D, Park CH, Barthelemy P, Bupathi M, Petrylak DP, et al. Primary analysis of TROPHY-U-01 cohort 3, a phase 2 study of sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based therapy. J Clin Oncol. 2023;41(6_suppl):518.CrossRef Grivas P, Pouessel D, Park CH, Barthelemy P, Bupathi M, Petrylak DP, et al. Primary analysis of TROPHY-U-01 cohort 3, a phase 2 study of sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based therapy. J Clin Oncol. 2023;41(6_suppl):518.CrossRef
6.
go back to reference Powles T, Necchi A, Duran I, Loriot Y, Ramamurthy C, Recio-Boiles A, et al. TROPHU-U-01 cohort 5: evaluation of maintenance sacituzumab govitecan (SG) plus zimberelimab (ZIM), ZIM, or avelumab in cisplatin-eligible patients (pts) with unresectable or metastatic urothelial cancer (mUC). J Clin Oncol. 2023;41(6_suppl):TPS598.CrossRef Powles T, Necchi A, Duran I, Loriot Y, Ramamurthy C, Recio-Boiles A, et al. TROPHU-U-01 cohort 5: evaluation of maintenance sacituzumab govitecan (SG) plus zimberelimab (ZIM), ZIM, or avelumab in cisplatin-eligible patients (pts) with unresectable or metastatic urothelial cancer (mUC). J Clin Oncol. 2023;41(6_suppl):TPS598.CrossRef
7.
go back to reference Duran I, Necchi A, Powles T, Loriot Y, Ramamurthy C, Recio-Boiles A, et al. TROPHY-U-01 cohort 6: Sacituzumab govitecan (SG), SG plus zimberelimab (ZIM), SG plus ZIM plus domvanalimab (DOM), or carboplatin (CARBO) + gemcitabine (GEM) in cisplatin-ineligible patients (pts) with treatment-naive metastatic urothelial cancer (mUC). J Clin Oncol. 2023;41(6_suppl):TPS592.CrossRef Duran I, Necchi A, Powles T, Loriot Y, Ramamurthy C, Recio-Boiles A, et al. TROPHY-U-01 cohort 6: Sacituzumab govitecan (SG), SG plus zimberelimab (ZIM), SG plus ZIM plus domvanalimab (DOM), or carboplatin (CARBO) + gemcitabine (GEM) in cisplatin-ineligible patients (pts) with treatment-naive metastatic urothelial cancer (mUC). J Clin Oncol. 2023;41(6_suppl):TPS592.CrossRef
8.
go back to reference Jain RK, Yang Y, Chadha J, Chatwal MS, Kish JA, Raymond S, et al. Phase I/II study of ipilimumab plus nivolumab combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma. J Clin Oncol. 2023;41(6_suppl):521.CrossRef Jain RK, Yang Y, Chadha J, Chatwal MS, Kish JA, Raymond S, et al. Phase I/II study of ipilimumab plus nivolumab combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma. J Clin Oncol. 2023;41(6_suppl):521.CrossRef
9.
go back to reference Sheng X, Yan X, Wang L, Shi Y, Yao X, Luo H, et al. Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma. Clin Cancer Res. 2021;27(1):43–51.CrossRefPubMed Sheng X, Yan X, Wang L, Shi Y, Yao X, Luo H, et al. Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma. Clin Cancer Res. 2021;27(1):43–51.CrossRefPubMed
10.
go back to reference Powles T, Yu EY, Iyer G, Campbell MT, Loriot Y, Santis MD, et al. Phase 2 clinical study evaluating the efficacy and safety of disitamab vedotin with or without pembrolizumab in patients with HER2-expressing urothelial carcinoma (RC48G001). J Clin Oncol. 2023;41(6_suppl):TPS594.CrossRef Powles T, Yu EY, Iyer G, Campbell MT, Loriot Y, Santis MD, et al. Phase 2 clinical study evaluating the efficacy and safety of disitamab vedotin with or without pembrolizumab in patients with HER2-expressing urothelial carcinoma (RC48G001). J Clin Oncol. 2023;41(6_suppl):TPS594.CrossRef
Metadata
Title
Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium
Authors
Jiazheng Yu
Siyu Wu
Rong Li
Yuanhong Jiang
Jianyi Zheng
Zeyu Li
Mingyang Li
Kerong Xin
Xiaojiao Guan
Shijie Li
Xiaonan Chen
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2023
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-023-01475-9

Other articles of this Issue 1/2023

Journal of Hematology & Oncology 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine